



Current Challenges in Hematology – 2nd Edition

Rome, 24-25 January 2024
NH VITTORIO VENETO
Corso d'Italia, 1, Rome

PRESIDENT
Alessandro Isidori

DAY 1
January 24th 2024

09.00 Congress open
Alessandro Isidori

09.15 SESSION I - SALA TIZIANO

MULTIPLE MYELOMA

Chairmen: Maria Victoria Mateos, Elena Zamagni

09.15 Biology of high-risk disease
Alessandra Romano • Catania

09.30 Management of high-risk patients
Roberto Mina • Turin

09.45 Bispecific antibodies and CAR-T:
data from clinical trials
Maria Victoria Mateos • Salamanca

10.00 Practical management of patients treated with
bispecific antibodies and CAR-T
Elena Zamagni • Bologna

10.15 Anti-BCMA targeted therapy in RRMM: data
from real life
Maria Teresa Petrucci • Rome

10.30 Discussion

10.45 SESSION II

LYMPHOMAS - HOW TO INCORPORATE NEW DRUGS IN CLINICAL PRACTICE

Chairmen: Umberto Vitolo, Maurizio Martelli

10.45 Brentuximab Vedotin
Luigi Rigacci • Rome

11.00 Polatuzumab Vedotin
Maurizio Martelli • Rome

11.15 Tafasitamab
Guido Gini • Ancona

11.30 Epcoritamab
Umberto Vitolo • Turin

11.45 Zanubrutinib
Alessandra Tedeschi • Milan

12.00 Mosunetuzumab
Marco Ladetto • Alessandria

12.15 Discussion

HONORARY PRESIDENTS

Giuseppe Visani
Adolfo de la Fuente Buergera

ORGANIZING COMMITTEE

Naval Daver
Felicetto Ferrara
Yngvar Floisand
Uwe Platzbecker
Giuseppe Visani
Umberto Vitolo
Elena Zamagni

12.30 - 13.30 SALA MASCAGNI

LUNCH MEETING JANSSEN NO ECM

Chairmen: Alessandro Isidori

12.30 Updated treatment options in NDMM
and first relapse
Silvia Mangiacavalli • Pavia

12.45 Evolving treatment paradigms in
relapsed refractory multiple myeloma setting
Elisabetta Antonioli • Florence

13.00 The future of CLL patient management:
a solid and innovative approach
Luca Laurenti • Rome

13.15 Discussion

13.45 - 14.45 SALA MASCAGNI

SIMPOSIO ABBVIE NO ECM

How to face current challenges in AML,
DLBCL, CLL?

Chairman: Alessandro Isidori

13.45 AML: How to improve outcomes in unfit
patients through an optimal Ven+Aza
management
Carmela Gurrieri • Padua

14.00 CLL: The benefits of fixed duration Ven
based regimens in both fit and unfit patients'
settings
Alessandro Sanna • Florence

14.15 DLBCL: Epcoritamab and Bispecific
Antibodies: Transforming the Care of R/R
DLBCL Patients

Gerardo Musuraca • Meldola

14.30 Discussion Q&A

14.45 - 15.30 SALA MASCAGNI

SIMPOSIO ASTRAZENECA NO ECM

Introduzione Alessandro Isidori

Il profilo farmacologico di Acalabrutinib:
l'integrazione di efficacia e sicurezza
Romano Danesi • Pisa
Marzia Varettoni • Pavia

SALA TIZIANO

16.00 Lecture: CAR-T: new paradigm in DLBCL ?
Paolo Corradini • Milan

16.15 SESSION III - SALA TIZIANO

CHALLENGES IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: Francesca Romana Mauro, Antonio Cuneo

16.15 Therapeutic options in CLL: first line
Francesca Romana Mauro • Rome

16.30 Therapeutic options in CLL: subsequent lines
Antonio Cuneo • Ferrara

16.45 Looking at the future: evolution of the
treatment Othman al Sawaf • Cologne

17.00 Clinical management of patients with CLL
Paolo Sportoletti • Perugia

17.15 Discussion

17.30 SESSION IV

MYELOPROLIFERATIVE NEOPLASMS

Chairmen: Francesco Passamonti, Massimo Breccia

17.30 Current challenges in polycythemia vera
Francesco Passamonti • Milan

17.45 New kids on the block:
rusfertide in polycythemia vera
Alessandro Isidori • Pesaro

18.00 Current management of patients with
myelofibrosis
Massimo Breccia • Rome

18.15 New drugs
Giuseppe Palumbo • Catania

18.30 Discussion

18.45 Day-1 Closing

19.00 - 20.00 SALA MASCAGNI

SIMPOSIO BEIGENE NO ECM

Le nuove evidenze dei BTKi nel trattamento del
paziente ematologico

19.00 Introduzione
A. Tedeschi • Milan A. Isidori • Pesaro

19.10 Linfomi indolenti ed aggressivi
G. Gini • Ancona

19.30 Macroglobulinemia di Waldenstrom
A. Tedeschi • Milan

19.50 Nuovi paradigmi nella
Leucemia Linfatica Cronica
G. Loseto • Bari

20.00 Conclusioni
A. Tedeschi • Milan A. Isidori • Pesaro



With the patronage of
SIE
Società Italiana di Ematologia



Current Challenges in Hematology – 2nd Edition

Rome, 24-25 January 2024
NH VITTORIO VENETO
Corso d'Italia, 1, Rome

HONORARY PRESIDENTS
Giuseppe Visani
Adolfo de la Fuente Buergera
ORGANIZING COMMITTEE
Naval Daver
Felicetto Ferrara
Yngvar Floisand
Uwe Platzbecker
Giuseppe Visani
Umberto Vitolo
Elena Zamagni

DAY 2
January 25th 2024

09.00 SYROS SPONSORED LECTURE NO ECM

09.30 SESSION V MYELODISPLASTIC SYNDROMES

Chairmen: Maria Teresa Voso, Alessandro Isidori

09.30 Prognosis: From to MDS
Maria Teresa Voso • Rome

09.45 Therapy: Standards and perspectives
Lionel Ades • Paris

10.00 Iron in MDS
Francesca Vinchi • New York

10.15 Immunotherapy in myeloid malignancies
Naval Daver • Houston

10.30 Discussion

10.40 Lecture: Challenges in treatment of immune
thrombocytopenia (ITP)
Elena Rossi • Rome

10.55 Coffee Break

11.15 SESSION VI ACUTE MYELOID LEUKEMIA

Chairmen: Naval Daver, Konstanze Dohner

11.15 Integrating new AML classifications in
clinical practice
Konstanze Dohner • Ulm

11.30 Treatment of high-risk AML
Alessandro Isidori • Pesaro

11.45 Mechanism of resistance and novel
combinations with Venetoclax-based treatment
in AML
Naval Daver • Houston

12.00 Targeting FLT-3 mutated AML
Alexander Perl • Philadelphia

12.15 Menin inhibition in acute leukemias
Cristina Papayannidis • Bologna

12.30 Discussion

12.40 Light Lunch

13.30 SESSION VII ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: Sabina Chiaretti, Cristina Papayannidis

13.30 New treatment strategies for Ph-like ALL
Sabina Chiaretti • Rome

13.45 Antibodies in MRD +ve ALL
Cristina Papayannidis • Bologna

14.00 CAR-T in childhood ALL: history of a
revolution
Franco Locatelli • Rome

14.15 Discussion

14.30 SESSION VIII ACUTE MYELOID LEUKEMIA (II)

Chairmen: Felicetto Ferrara, Adriano Venditti

14.30 MRD and treatment decision making
Adriano Venditti • Rome

14.45 Fitness and treatment decision making in
patients not eligible for intensive chemotherapy
Felicetto Ferrara • Naples

15.00 Targeting IDH1 and IDH 2
Adolfo de la Fuente Buergera • Madrid

15.15 Maintenance therapy
Giuseppe Visani • Pesaro

15.30 SESSION IX STEM CELL TRANSPLANTATION

Chairmen: Yngvar Floisand, Alessandro Isidori

15.30 Which AML patients should we transplant
in 2023?
Yngvar Floisand • Oslo

15.45 Treosulfan-based conditioning regimen: a
new paradigm?
Michele Malagola • Brescia

16.00 Diagnosis and treatment of VOD/SOS after
allo-HSCT
Simona Sica • Rome

16.15 Discussion

16.30 Congress Close
SEE YOU IN 2025

CME INFO & REGISTRATION

Event n. 2773 - 366183 - Objective n. 3
13 CME Credits for : Hematologists and Biologists
Free registration: www.proeventi.it
pin : current2024 (DEPP ECM APP)
provider n. 2773



www.proeventi.it
info@proeventi.it

CONFERENCE VENUE

NH VITTORIO VENETO
[Corso d'Italia, 1, 00198 Roma RM](#)

WITH THE UNRESTRICTED EDUCATIONAL GRANT OF

DIAMOND SPONSOR



SILVER SPONSOR



BRONZE SPONSOR

